Literature DB >> 7738717

MDM2 and CDK4 gene amplification in Ewing's sarcoma.

M Ladanyi1, R Lewis, S C Jhanwar, W Gerald, A G Huvos, J H Healey.   

Abstract

Amplification of the MDM2 gene, which maps to chromosome band 12q13 and encodes a p53-binding protein, may result in functional inactivation of p53 and has been observed in various bone and soft tissue sarcomas. Published studies have included few cases of Ewing's sarcoma (ES) or peripheral neuroectodermal tumour (PNET), a tumour group in which alterations of the p53 pathway have so far not been extensively studied. We examined two ES cell lines, RD-ES and SK-ES-1, and 30 specimens from 27 patients (24 ES, 6 PNET; 19 primary, 4 local recurrence, 7 metastasis) for MDM2 gene amplification by Southern blot analysis. All 30 clinical specimens had been confirmed to contain sufficient ES/PNET DNA by the demonstration of a rearrangement of the t(11;22)-associated EWS gene using an EWS cDNA probe on the same blots. MDM2 gene amplification was detected in 3 of 30 specimens (10 per cent), including two ES and one PNET, but in neither of the cell lines. The three cases with amplification were morphologically typical primary tumours. Two of the three cases also showed co-amplification of the CDK4 gene, which encodes a cyclin-dependent kinase and also maps to band 12q13. Clinically, all three cases had metastatic disease at diagnosis, compared with only 1 of 15 MDM2-negative cases where the primary tumour was studied. The difference was statistically significant (P = 0.005), suggesting an association of MDM2 amplification with advanced stage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738717     DOI: 10.1002/path.1711750209

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection.

Authors:  W Henning; G Rohaly; T Kolzau; U Knippschild; H Maacke; W Deppert
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases.

Authors:  K M Latham; S W Eastman; A Wong; P W Hinds
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

Review 4.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

5.  Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types.

Authors:  P Thorner; J Squire; S Chilton-MacNeil; P Marrano; J Bayani; D Malkin; M Greenberg; A Lorenzana; M Zielenska
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Is There a Predisposition Gene for Ewing's Sarcoma?

Authors:  R L Randall; S L Lessnick; K B Jones; L G Gouw; J E Cummings; L Cannon-Albright; J D Schiffman
Journal:  J Oncol       Date:  2010-03-15       Impact factor: 4.375

7.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

8.  The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.

Authors:  J Keleti; M M Quezado; M M Abaza; M Raffeld; M Tsokos
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

Review 9.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

10.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.